10 manufacturers medicines with serious diseases chosen at the beginning of the year for negotiate prices with the US government agreed to join the talks, the White House announced on Tuesday.
The announcement comes despite pharmaceutical companies’ continued rejection of the initiative.
Where the federal government seeks to negotiate prices on medicines covered by Medicare, health insurance program for those over 65 years old on deer.
The historical Inflation Reduction Act (IRA), President Joe Biden’s major legislative policy package for energy transition and social reforms that he signed last year, allows Medicare to begin negotiating energy prices. medicines for the first time in its almost 60 years of existence.
Under the law, the federal government you are limited at first to only choose 10 drugs for price negotiations, but the program may be expanded in the following years.
- This is an important measure given that The United States pays an average of 2.5 times more for drugs prescribed than in other developed countries, according to a study by the Rand Corporation.
“In total, the 10 medicines selected for negotiation represented $3.4 billion in out-of-pocket costs for approximately nine million Medicare enrollees by 2022″the White House said in a statement released Tuesday.
Los 10 medicines including fill from AstraZeneca, used against diabetes and heart failure, Imbruvica from Pharmacycls, used to treat blood cancer, and anticoagulant Eliquis (apixaban), used by more than 3.7 million Medicare beneficiaries.
The change in prices for 10 drugs will not take effect until January 2026.
